San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Rezo Therapeutics is raising $80,129,936.00 in new funding. Sources indicate as part of senior management Chief Scientific Officer, Sourav Bandyopadhyay played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Rezo Therapeutics
Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. Our Founders and members of the Board are a group of esteemed, world-class scientists from the University of California, San Francisco: Nevan Krogan, Kevan Shokat, Sourav Bandyopadhyay, Natalia Jura, as well as renowned biotech executives George Scangos and Norbert Bischofberger. These leaders bring with them a strong track record of amazing discoveries and scientific breakthroughs, leading to very successful companies and many FDA approved drugs.

To learn more about Rezo Therapeutics, visit http://www.rezotx.com/

Contact:
Sourav Bandyopadhyay, Chief Scientific Officer
415-310-4524

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved